Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose

NCT01171989 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

391

Enrollment

INDUSTRY

Sponsor class

Conditions

Tetanus
Diphtheria
Haemophilus Influenzae Type b
Hepatitis B
Poliomyelitis
Acellular Pertussis
Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b-Neisseria Meni

Interventions

BIOLOGICAL: GSK2202083A vaccine
BIOLOGICAL: Infanrix hexa™
BIOLOGICAL: Menjugate™
BIOLOGICAL: NeisVac-C™
BIOLOGICAL: Synflorix™

Sponsor

GlaxoSmithKline